After the Russian direct investment Fund (RDIF) has invested hundreds of millions of rubles in the development of Japanese analog medication favipiravir to apply it to treat COVID-19, the original drug has not shown effectiveness against coronavirus infection. This was reported in conducting relevant research to the Japanese Institute of health Fujita. Meanwhile, in Russia which was created an analogue of favipiravir actively used on patients. In addition, his version of this same medication has registered “R-Pharm” Alexey Repik.Clinical study of the drug avigan (international nonproprietary name — favipiravir) the Japanese company Fujifilm has not shown conclusive results of its effectiveness for the treatment COVID-19. About it reports Reuters with a reference to who conducted the study of Fujita Health University. The tests were carried out from March to may with the participation of 89 patients throughout Japan.Avigan was developed by Fujifilm subsidiary and was approved in 2014 in Japan as an emergency treatment for flu. In the beginning of 2020, Prime Minister Shinzo Abe has suggested that avian can be effective against COVID-19. But clinical trials, according to pharmaceutical industry dedicated to the edition “news GMP”, was arrested due to the lack of patients.At the same time to use this medicine for the treatment of coronavirus infection began in China in February a local company Zhejiang Hisun Pharmaceutical said that it has received approval for the sale of favipiravir as a potential means from COVID-19. And in March about plans to invest “hundreds of millions of dollars” in developing its own analogue of favipiravir reported RDIF. The creation of the drug under the brand aviewer was conducted jointly with pharmaceutical company Chemrar. The Ministry of health has reduced the period of withdrawal of the drug on the market, and the study was conducted after registration, and it was included in the list recommended for the treatment of coronavirus infection. However, as said “Kommersant”, chief infectionist of the Ministry Vladimir closets, in the preparation of the provisional methodological recommendations of the Ministry of health relied on data from clinical trials of favipiravir in Russia and they showed its effectiveness.Chairman of the Board of Directors at “Chemrar” Andrey Ivashchenko claims with reference to the Japanese scientists that the results of clinical studies of favipiravir are provisional. Yet they do not allow to make definite conclusions about the effectiveness of drugs against COVID-19, said Mr. Ivashchenko. Analogue RDIF and “Chimera” in turn, was established on the basis of a more pure substance, which allowed to increase the dose in the treatment without an increase in side effects, says Andrey Ivaschenko. According to him, the tests were carried out more than 700 patients and Russian developers came to p��attention more optimal schemes of application, different from the schemes used in conventional flu. In particular, favipiravir was more effective for the treatment of patients in mild and moderate stages of the disease, than severe.”Now with the Japanese Corporation Fujufilm we are discussing data transfer to clinical trials and further joint work on the preparation”,— said Andrey Ivashchenko.According to Vladimir Chulanov, differences in test results RDIF and Fujifilm can be associated with “design research” used by the dosage of the drug, population characteristics, including individual genetic factors. Meanwhile, on 6 July, an analog of favipiravir under the brand “Cornavin” registered “R-Pharm” Alexey Repik. “B” sent a request to the company.Maria Kotova
